Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
Skin Therapy Lett
; 29(1): 1-4, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-38271532
ABSTRACT
Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Dermatopatias Vesiculobolhosas
/
Exantema
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Canadá